Chemical modifications of lead compounds were carried out, potent antitubercular agents with MIC as low as 0.05 µM.
In this study, we synthetized a series of 2-(quinolin4uloxy)acetamides for further evaluation of MICs using drug-susceptible and drug-resistant Mtb strains. Moreover, a preliminary structure-activity relationship (SAR) study was also presented.
Resultados e Discussão
The syntheses of 2-(quinolin-4uloxy)acetamides 2, 5a-o and 5q-t were conducted in two synthetic steps 3 . First, the 2-bromo-N-arylacetamides 4a-o and 4q-t were prepared by the acylation reaction of substituted anilines or 1(2)-naphthylamine using bromoacetyl chloride in the presence of 4-dimethyl aminopyridine (DMAP) as a catalyst. Subsequently, 2-(quinolin-4-yloxy)acetamides 2, 5a-o, and 5q-t were synthesized by the O-alkylation reaction of 4-hydroxyquinolines 3a-b with 2-bromo-Narylacetamides 4a-o and 4q-t in the presence of potassium carbonate using N,N-dimethylformamide (DMF) as the solvent (Scheme 1). Scheme 1. Reaction conditions: i) DMF, K 2 CO 3 , 25 °C, 16 h. The synthesized compounds were evaluated in a whole-cell assay against M. tuberculosis strain H37Rv conducted by the Resazurin Assay method using isoniazid (INH) as the standard drug. The most active molecules against M. tuberculosis H37Rv were tested against a panel of clinically isolated drug-resistant strains and in a macrophageinfected model. In addition, thermodynamic solubility, metabolic stability in human liver S9 fraction, cytochrome P450 inhibition, and cardio toxicity risk were also evaluated.
3
The simplicity, easily accessible reactants and reagents, reasonably good yields (32-98%), and high purity make this synthetic method attractive. Further, the synthesized compounds were active against drug-resistant strains and were devoid of apparent toxicity to Vero and HaCat cells (IC 50 s ≥ 20 µM). In addition, the 2-(quinolin-4-yloxy)acetamides showed intracellular activity against the bacilli in infected macrophages with action similar to rifampin. Finally, the most potent compounds exhibited low to moderate metabolic stabilities, low risks of drug−drug interactions based on CYP450 inhibition studies with no signs of cardiac toxicity in zebrafish (Danio rerio) at 5 µM.
Conclusões
These data indicate that this class of compounds may furnish candidates for future development to, hopefully, provide drug alternatives for tuberculosis treatment.
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